Abstracts

Together Take Me Home: Launch of a National HIV Self-Test Distribution Program, March-December 2023

Background: HIV testing is the first step to accessing both HIV treatment and prevention services. HIV self-testing is a key strategy for overcoming barriers to HIV testing. Methods: The Together TakeMeHome (TTMH) program is a CDC-sponsored, direct-to-consumer, HIV self-test distribution program. CDC’s Let’s Stop HIV Together campaign implemented marketing on platforms including social media, dating…

Improving Posthospital Outcomes in People With HIV: A Multicenter Randomized Trial in Tanzania

Background: In spite of the widespread availability of antiretroviral therapy (ART), people living with HIV (PLWH) still experience poor outcomes with high mortality during and after hospital admissions. Delayed linkage to HIV care after hospital discharge is a major risk factor. We tested a linkage case management intervention (‘Daraja’ = ‘Bridge’ in Kiswahili) to address…

Role of Cytoskeleton and Adhesion in a Rare Subset of HIV-Infected Cells That Resist CTL

Background: Although latency is a key mechanism of HIV persistence, the reservoir continues to be shaped by cytotoxic T lymphocytes (CTL) pressure under antiretroviral therapy (ART). Growing evidence suggests that this selects for reservoir-harboring cells with CTL-resistant properties, including over-expression of BCL-2, PVR and the granzyme B inhibitor SERPINB9. Here, we lay a foundation for…

Adherence Benchmarks for TFV-DP in DBS and PBMCs for African Women Using FTC/TDF PrEP

Background: Intracellular tenofovir-diphosphate (TFV-DP) concentration benchmarks in dried blood spots (DBS) from oral emtricitabine-tenofovir disoproxil fumarate (F/TDF) pre-exposure prophylaxis (PrEP) have informed adherence-concentration-efficacy relationships for men who have sex with men, derived from observed dosing studies in US populations. Similar thresholds for African cisgender women have not been defined. Methods: Between April 2022 and June…

Preclinical Pharmacokinetic Assessment of a Hepatitis C Virus Long-Acting Injectable Formulation

Background: Eight weeks of daily, oral glecaprevir (G) and pibrentasvir (P) cures 98% of people with chronic Hepatitis C Virus (HCV) infection. However, major challenges, including medication adherence and loss of patients to follow-up, impede delivery of this combination. As such, 58 million people remain infected worldwide. A long-acting injectable (LAI) providing 8 weeks of…